Sengenics, a leading commercial stage precision medicine focused company, today announced that Dr Arif Anwar, CEO of Sengenics, has been invited to present at the Biotech Showcase™ during the upcoming 38th Annual J.P. Morgan Healthcare Conference week in San Francisco.
Dr Arif Anwar will present an overview of the commercialisation strategy of the company, as well as applications of its well-differentiated and patented KREX™ technology for intra-disease stratification and autoimmune and cancer immunotherapy drug response prediction. The identity of the autoantibody biomarkers discovered from these applications can also guide drug development decision-making for the pharmaceutical industry, allowing for the early elimination of poor drug candidates. For clinical stage candidates, this can result in very significant cost savings as well as acceleration of the best candidates towards faster FDA drug approval. For commercially launched drugs, KREX™ offers unparalleled opportunities to gain market share by identifying new true responders.
Sengenics currently has partnerships with 9 out of the top 20 pharma to co-develop complementary and companion diagnostic tests for autoimmune and cancer immunotherapy drugs. The company has commenced the process for obtaining FDA 510(k) approval for several of these tests and plans to launch them in 2020. Sengenics’ key value drivers, which are derivatives from enhancing precision medicine, are primarily based on maximising the probability that drugs are prescribed only to patients who have a greater than 90% chance of responding to them. These new Sengenics tests offer a compelling business case for the pharmaceutical industry as well as medical insurance companies, whilst ultimately delivering upon the promise of precision medicine for autoimmune and cancer immunotherapy drugs.
Details of Sengenics’ presentation are as follows:
Event: Biotech Showcase™ 2020
Date: Tuesday, January 14, 2020
Time: 2:30 PM Pacific Time (5:30 PM Eastern Time)
Title: Realising the Potential of Precision Medicine for Autoimmune and Cancer Drugs using Sengenics’ KREX Technology
Location: Franciscan B (Ballroom Level), Hilton San Francisco Union Square – 333 O'Farrell Street
The presentation document will be available on the Sengenics website in the "Downloads" section on the same day.
Sengenics is a functional proteomics company that leverages its patented KREX™ technology for production of full-length, correctly folded and functional proteins. KREX™ was invented and patented by Professor Jonathan Blackburn whilst he was a member of the faculty at the University of Cambridge.
The key application of KREX™ is the discovery of autoantibody biomarkers for two core medical use cases. Firstly, stratification of patients undergoing treatment with autoimmune or cancer drugs into responders, non-responders and those that may exhibit severe immune-related adverse events (irAEs). Secondly, identification of autoantibody biomarkers that may be used to diagnose cancer, autoimmune or neurodegenerative conditions years before conventional diagnostic tests. Some autoantibodies that are identified as diagnostic biomarkers may be protective and have potential in themselves as therapeutic biomolecules.
Sengenics Corporation Pte Ltd
Business Development and Partnerships
Andrew James Jackson
Director, Europe & North America
Sengenics Corporation Pte Ltd